drugset / Trial / NCT06804811

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

NCT06804811

Phase 3 Recruiting 250 enrolled Incyte Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.

Timeline

Start
2025-11-13
Primary completion
2027-04-30
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 0.75 % Topical
Subject Ruxolitinib Small molecule 1.5 % Topical

Indications